HCC: Key topics discussed at ASCO GI & EASL 2022

December 06, 2023 00:13:11
HCC: Key topics discussed at ASCO GI & EASL 2022
COR2ED - Oncology Medical Conversation
HCC: Key topics discussed at ASCO GI & EASL 2022

Dec 06 2023 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode

December 06, 2023 00:31:03
Episode Cover

Prostate cancer: Genetic testing and PARP inhibitors in prostate cancer

COR2ED Medical Education: Joanne Chien, Nurse Practitioner specialising in urologic cancers at Stanford Health Care in Palo Alto, California, and Dr Alexander Wyatt, Assistant...

Listen

Episode

December 06, 2023 00:25:18
Episode Cover

Upper GI cancer Highlights from ASCO GI 2023 - Part 1

This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023.  Dr Nataliya Uboha (University of Wisconsin, USA)...

Listen

Episode

December 06, 2023 00:17:57
Episode Cover

Colorectal and gastric cancer: Current and future therapeutic approaches. Part 3 - Future developments

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité...

Listen